Rapid worsening of IgM anti-MAG demyelinating polyneuropathy during rituximab treatment

Journal of the Peripheral Nervous System

Volumn 18, Issue 2, 2013, Pages 189-191

  Stork, Abraham C J ^a   Notermans, Nicolette C ^a   Vrancken, Alexander F J E ^a   Cornblath, David R ^b   Van Der Pol, W Ludo ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI MYELIN ASSOCIATED GLYCOPROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; PLACEBO; PROTEIN ANTIBODY; RITUXIMAB; UNCLASSIFIED DRUG;

ANTIBODY TITER; ATAXIA; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GENERAL CONDITION DETERIORATION; HUMAN; HYPESTHESIA; LETTER; MONOCLONAL IMMUNOGLOBULINEMIA; MUSCLE WEAKNESS; NERVE CONDUCTION; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORY DYSFUNCTION; WEAKNESS;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE PROGRESSION; ELECTROPHYSIOLOGY; FEMALE; HUMANS; IMMUNOGLOBULIN M; IMMUNOLOGIC FACTORS; MALE; MYELIN-ASSOCIATED GLYCOPROTEIN; PARAPROTEINEMIAS; POLYRADICULONEUROPATHY;

EID: 84879405998     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/jns5.12018     Document Type: Letter

References (9)

1. Broglio L, Lauria G, (2005). Worsening after rituximab treatment in anti-MAG neuropathy. Muscle Nerve 32: 377-378.
2. Dalakas MC, Rakocevic G, Salajegheh Dambrosia JM, Hahn AF, Raju R, McElroy B, (2009). Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65: 286-293.
3. Gironi M, Sarasella M, Ceresa L, Calvo M, Ferrante P, Merli F, Nemni R, (2006). Clinical and immunological worsening in a patient affected with Waldenström macroglobulinemia and anti-MAG neuropathy after treatment with rituximab. Haematologica 91: e51-e52.
4. Larue S, Bombelli F, Viala K, Neil J, Maisonobe T, Bouche P, Musset L, Fournier E, Leger JM, (2010). Non-anti-MAG DADS neuropathy as a variant of CIDP: clinical, electrophysiological, laboratory features and response to treatment in 10 cases. Eur J Neurol 18: 899-905.
5. Leger JM, Viala K, Nicolas G, Creange A, Vallat J, Preux P-M, for the RIMAG study group (2011). A randomized placebo-controlled trial of rituximab in IgM anti-myelin associated protein antibody associated neuropathy (RIMAG study). J Peripher Nerv Syst 16 (Suppl. 3): S73.
6. Lunn MP, Nobile-Orazio E, (2012). Immunotherapy for IgM anti-myelin-associated glycoprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 5: CD002827.
7. Niermeijer JM, Eurelings M, Lokhorst HL, van der Pol WL, Franssen H, Wokke JH, Notermans NC, (2009). Rituximab for polyneuropathy with IgM monoclonal gammopathy. J Neurol Neurosurg Psychiatry 80: 1036-1039.
8. Renaud S, Gregor M, Fuhr P, Lorenz D, Deuschl G, Gratwohl A, Steck AJ, (2003). Rituximab in the treatment of anti-MAG associated polyneuropathy. Muscle Nerve 27: 611-615.
9. Rojas-Garcia R, Gallardo E, de Andres I, de Luna N, Jiazrez C, Sanchez P, Illa I, (2003). Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 61: 1814-1816.